Drug Profile
Larotaxel
Alternative Names: 109,881; PNU 100940; RPR 109881A; RPR109881; Taxoid 109881; XRP9881Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi; sanofi-aventis
- Class Antineoplastics; Taxanes
- Mechanism of Action Tubulin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bladder cancer; Breast cancer; Non-small cell lung cancer; Pancreatic cancer
Most Recent Events
- 31 Dec 2010 Development discontinued for Bladder cancer (first-line therapy, metastatic disease) during 2010 in Argentina (IV)
- 31 Dec 2010 Development discontinued for Bladder cancer (first-line therapy, metastatic disease) during 2010 in Australia (IV)
- 31 Dec 2010 Development discontinued for Bladder cancer (first-line therapy, metastatic disease) during 2010 in Belgium (IV)